Background {#Sec1}
==========

Extracellular vesicles (EVs) are powerful biological entities released by cells that contain molecules that can promote changes in their targets. EVs have therefore been studied for clinical applications as vaccines, immunosuppressants, or stimulators of repair and differentiation processes \[[@CR1]--[@CR3]\]. EV is an umbrella term that includes a variety of different released vesicles such as exosomes and microvesicles (MVs). The term "exosomes" is often used to describe vesicles that originate from the fusion of endosomal-originated multivesicular bodies with the plasma membrane. This biogenesis sets them apart from other EVs, for example, those that are released through the budding of the plasma membrane, which are usually referred to as MVs \[[@CR4]\]. Because of their distinct biogenesis, MVs are usually larger than exosomes (typically, exosomes are less than 200 nm in diameter, while MVs can range in size up to 1000 nm in diameter), but overlapping of these size ranges can occur. Different isolation protocols focus on the separation of a fraction enriched in exosomes, MVs, or both \[[@CR5]\]. Because the study of EVs is a recent field, many studies have used heterogeneous nomenclature when reporting data regarding EVs. It is common to find terms such as "exosomes," "MVs," and "microparticles" referring to an indistinct population of EVs \[[@CR5]\]. For the sake of uniformity, we are here including all of these studies under the term "EVs."

Although many functions have been ascribed to EVs, especially involvement in cellular communication, their roles in vivo are still poorly understood. There are likely still major functions and effects that remain unknown, and the immunological effects of EVs released by different cells in pathological states are still poorly studied. On the other hand, because the sorting of molecules to these vesicles and the patterns of EV release are known to be reflective of their originating cell type and physiological state, the EV fraction of extracellular fluids can be very informative. Consequently, substantial attention has been directed towards the use of "liquid biopsies" containing EVs from injured tissue and tumors for detection of disease biomarkers in the hope of developing less invasive diagnostic procedures with high sensitivity and specificity \[[@CR6]\]. The sorting of molecules into EVs is still a somewhat obscure process, but it clearly involves the enrichment of distinct proteins and nucleic acids. Particular attention has been given to the protein and RNA content of EVs as agents for altering gene and protein expression in target cells \[[@CR7]\].

Currently, the focus on secreted vesicles from stem cells has been most extensively directed to mesenchymal stem cells (MSCs), which are also called mesenchymal stromal cells. These cells are multipotent cells that can be isolated from a variety of adult tissues \[[@CR8]\]. The most studied MSCs are isolated from bone marrow (BM-MSCs), adipose tissue (AD-MSCs), or umbilical cord blood (UC-MSCs). The isolated MSCs have been generally heterogeneous and containing stem cells, committed progenitors, and differentiated cells \[[@CR9]\]. Hereafter, we will discuss MSCs broadly and independently of their tissue of origin. When not mentioned in the text, the tissue from which the cells were derived is stated in the tables included in this review.

Although there are no specific markers for MSCs, they are usually characterized by their ability to differentiate into at least three lineages of cells of mesodermal origin (osteoblasts, chondroblasts, and adipocytes) upon chemical induction in vitro \[[@CR10]\] as well as by the absence of hematopoietic lineage markers but the presence of surface-associated markers such as CD44 and CD90 \[[@CR11]\]. MSCs support their niches in vivo by nurturing and promoting the proliferation and differentiation of surrounding cells. When transplanted for cell therapy, these cells migrate to sites of inflammation and injury and are well known for their ability to promote immunomodulation and tissue repair in a wide range of disease models \[[@CR12]\]. Nevertheless, they typically do not permanently engraft in the injured tissue when transplanted without a scaffold, and thus they only transiently influence the target tissues.

The secretomes of MSCs and their vesicles are of particular interest because these cells are mostly intended to be used for cell therapy due to their paracrine/endocrine effects rather than their differentiation potential \[[@CR13]--[@CR16]\]. Besides the soluble factors present in these cells' secretomes, such as growth factors and cytokines, the supernatant of MSC cultures is enriched with EVs. Many examples of pre-clinical data suggest that the EVs derived from MSCs carry over the therapeutic effects of their originating cells, and using EVs instead of the cells themselves can have advantages such as: Bypassing most of the safety concerns with regard to cell therapy, such as cellular contamination with oncogenic cells and uncontrolled cell division \[[@CR16]\];Enabling a wide range of potential manipulations of the particles for improvements in delivery and desired effect; andFacilitating the development of methods to optimize the use of MSCs to obtain a higher yield of final therapeutic product because these cells often require invasive procedures in order to be harvested \[[@CR17]\].

MSCs are also very responsive to environmental changes, showing different secretion profiles and phenotypes upon different stimuli in vitro, which can be related to their great dynamics in responding to different inflammatory or injured environments in vivo. Treatment of MSCs with EVs derived from other cells such as mast cells and epithelial cells influences their phenotype, as do treatments with soluble factors and changes in the cell culture conditions \[[@CR18], [@CR19]\]. It would be of great interest for the scientific community to have more control over MSCs' immunomodulation and differentiation abilities in order to design more effective and specific treatment strategies, both for direct cell therapy and for EV-mediated therapy.

MSC-derived EVs have emerged as an attractive mediator of immunomodulation and regenerative effects in various animal models. EV-based approaches have already been recognized as a safe and attractive therapeutic intervention, but one significant limitation is the typically low yield of EVs. To overcome this, several high-throughput procedures have been applied for large-scale EV production. Recent studies have utilized EV-mimetic nanovesicles produced from adipose stem cells as well as tumor cells by serial extrusion in order to overcome the low yield normally associated with naturally produced EVs \[[@CR20]--[@CR22]\]. Moreover, in many previous and ongoing studies, a variety of biophysical and biochemical cues have been shown to contribute to the therapeutic effect of EVs and to increase their level of production.

EV-based therapy also faces challenges regarding the purity of EV preparations \[[@CR23]\]. Our PubMed literature search with the terms "MSCs + extracellular vesicles + exosomes + microvesicles" identified several different methods for EV isolation (Fig. [1](#Fig1){ref-type="fig"}). More than half of the articles used only ultracentrifugation, and about 27% used commercial kits, mostly based on protein precipitation protocols. Only about 19% of the articles used some method that separated free secreted proteins from EVs (e.g., density gradient, filtration, and anion-exchange). In order to bring unanimity to our common knowledge of EV-derived functions, it is essential to study the true components of MSC-derived EVs separately from secreted proteins. Producing clean MSC-EV preparations will accelerate the translation of basics findings into clinic practice. Fig. 1Experimental methods for isolation of MSC-EVs. A total 126 articles were used to analyze the isolation method. Most studies have been conducted using EVs isolated by ultracentrifugation and with commercial kits such as ExoQuick-TC. TFF, tangential flow filtration

In this review, we discuss the development of MSC-derived extracellular vesicles (MSC-EVs) for therapeutic applications. First, we will discuss components of MSC-EVs and their roles in different in vivo and in vitro models, and then we will discuss some of the possibilities for manipulating MSCs in order to improve or alter their secretion of EVs and thus improve their therapeutic potential.

Wherein lies the therapeutic potency of MSC-EVs? {#Sec2}
------------------------------------------------

MSCs fulfill their roles in the body via direct cell-to-cell crosstalk as well as through the secretion of an extensive spectrum of soluble factors \[[@CR24]\]. Major soluble mediators secreted by MSCs include cytokines, growth factors, and miRNA, which have a wide variety of therapeutic effects ranging from tumor modulation, immunosuppression, and angiogenesis to tissue regeneration \[[@CR25]--[@CR27]\]. Recently, several groups have begun to find another functional component in conditioned media (CM) from MSCs apart from these soluble factors. Bruno et al. showed that fractioned MSC-CM by ultracentrifugation suppressed acute tubular injury in mice, and this pelleted fraction included nanosized vesicular structures \[[@CR28]\]. Another group utilized the EV fraction acquired by HPLC-derived size exclusion, which included vesicles with EV marker proteins, to reduce the size of acute myocardial infarction, which had already been accomplished in a previous study using MSCs and soluble factors \[[@CR29]\]. In addition to the aforementioned studies using MSC-CM to identify the therapeutically functional EVs, there are about 126 published articles that address the therapeutic function of EVs in a variety of disease models. Here, we will highlight the MSC-EV-associated cargos (proteins and nucleic acids) that have been shown to have distinct functional effects (Fig. [2](#Fig2){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}, and Additional file [1](#MOESM1){ref-type="media"}: Table S1). Fig. 2Components of MSC-derived EVs and their related therapeutic potential. The different circles show the suggested vesicular protein, mRNA, and miRNA components mediating the immune modulation, regeneration, and tumor growth effects of MSC-EVs. Abbreviations: MSC, mesenchymal stem cell; EVs, extracellular vesicles; PDGF-D, platelet-derived growth factor-D; COX2, cyclooxygenase 2; PGE~2~, prostaglandin E2; CCR2, C-C chemokine receptor type 2; KGF, keratinocyte growth factor; Ang-1, angiopoietin-1; HGF, hepatocyte growth factor; IGF-1R, insulin-like growth factor 1 receptor; IL-10, interleukin-10; UBR2, ubiquitin protein ligase E3 component n-recognin 2; FGF19, fibroblast growth factor 19 Table 1Overview of MSC-EV-related studies conducted in animal models and in vitro for various diseasesMSC originModelIn vivo/in vitro potencyAssociated moleculeRef.H - ADAngiogenesisIncreased angiogenic capacity of endothelial cellsmiR-125a\[[@CR122]\]H - ADProstate cancerDecreased proliferation and increased apoptosismiR-145\[[@CR65]\]H - BMOptic nerve crushPromoted regeneration of retinal ganglion cells axonsArgonaute-2\[[@CR34]\]H - BMLeukocyte activation (in vitro)Decreased inflammatory cytokines in leukocytesCOX2/PGE~2~\[[@CR35]\]H - BMNasopharyngeal carcinomaPromoted nasopharyngeal carcinoma cell growthFGF19\[[@CR38]\]H - BMBreast cancerInhibited endothelial cell migration and tube formation using supernatants from EV-treated breast cancer cellsmiR-100\[[@CR123]\]H - BMIntervertebral disc degenerationInhibited nucleus pulposus cell apoptosismiR-21\[[@CR54]\]H - BMCardiomyocyte contractility (in vitro)Increased contractilitymiR-21p\[[@CR124]\]H - BMGastric cancerIncreased gastric cancer cell migration and invasionmiR-221\[[@CR69]\]H - BMMetastatic breast cancerInduced dormancymiR-23b\[[@CR125]\]H - BMAcute myeloid leukemiaDifferent patterns of miRNA expression in EVsmiR-26a-5p, miR-101-3p, miR-23b-5p, miR-339-3p, miR-425-5p\[[@CR126]\]H - BMSkeletal muscle regenerationIncreased myogenesis and angiogenesismiR-494\[[@CR127]\]H - BMAcute kidney injuryRecovery from renal injurymRNA (CCNB1, CDK8, CDC6)\[[@CR128]\]H - DPIschemiaIncreased angiogenesisJagged1\[[@CR31]\]H - EMBOsteochondral defectIncreased cartilage repairCD73\[[@CR33]\]H - ENDCardiac infarction (in vitro)Anti-apoptotic/anti-angiogenic effects and cardioprotectionmiR-21\[[@CR59]\]Human gliomaGlioma stem cell activation (in vitro)Increased glioma stem cell tumorigenicitymiR-1587\[[@CR129]\]H - PLHindlimb ischemiaIncreased proangiogenic effectVEGF/miR-126\[[@CR92]\]H - UCMyocardial infarctionIncreased endothelial cell migration and tube formationPDGF-D\[[@CR32]\]H - UCCisplatin-injured renal tubular epithelial cells (in vitro)Protected against cisplatin-induced injury in renal tubular epithelial cells14-3-3ζ\[[@CR37]\]H - UCHypoxia-ischemia (in vitro)Anti-apoptotic effectmiR-let-7e, miR-let-7a\[[@CR130]\]H - UCHepatitis (in vitro)Protected against infection by hepatitis C virusmiR-let-7f, miR-145, miR-199a, miR-221\[[@CR66]\]H - UCSepsisIncreased survival in mice and decreased inflammatory cytokines in macrophagesmiR-146a\[[@CR85]\]H - UCSkin defectReduced scar formation and myofibroblast developmentmiR-21, miR-23a, miR-125b, miR-145\[[@CR56]\]H - UCSkin defect in diabetesPromoted healing of cutaneous woundsmiR-let-7b\[[@CR84]\]M - BMAcute kidney injuryRecovery from renal injuryCCR2\[[@CR36]\]M - BMKidney transplantationIncreased graft survivalmiR-146a\[[@CR131]\]M - BMSystemic sclerosisIncreased osteogenesis and decreased adipogenesismiR-151-5p\[[@CR132]\]M - BMBreast cancerDecreased angiogenesismiR-16\[[@CR133]\]M - BMHematopoietic cell activation (in vitro)Decreased autophagy and rejuvenating effects depending on agemiR-17, miR-34a (negative effect), RNA (positive effect)\[[@CR134]\]M - BMAlzheimer's diseasePrevented cognitive declinemiR-21\[[@CR55]\]M - BMMyocardial infarctionPromoted cardiac protectionmiR-210\[[@CR91]\]M - BMHindlimb ischemiaRestored blood perfusion and promoted angiogenesismiR-210-3p, VEGF\[[@CR135]\]M - BMCardiac infarctionDecreased cardiac fibrosismiR-22\[[@CR136]\]M - BMSepsisRecovered cardiac functionmiR-223\[[@CR137]\]M - BMGastric cancerIncreased proliferation and migrationUBR2\[[@CR39]\]M - EMBAngiogenesisIncreased angiogenic capacity of endothelial cellsmiR-30b\[[@CR138]\]R - ADErectile dysfunction in diabetesRestored erectile functionmiR-126, miR-130a, miR-132, miR-let7b, miR-let7c\[[@CR139]\]R - BMRenal fibrosis (in vitro)TGF-β induced epithelial mesenchymal transition in HK2 cellsmiR-294, miR-133b-3p\[[@CR140]\]R - BMStrokeNeuroprotective effectsmiR-133b\[[@CR141]\]R - BMMiddle cerebral artery occlusionPromoted neurite outgrowthmiR-133b\[[@CR142]\]R - BMColitisDecreased colitis-associated fibrosismiR-200b\[[@CR143]\]R - BMIschemic cardiomyopathy (in vitro)Reduced oxidative injurymiR-21\[[@CR58]\]Abbreviations: *MSC* mesenchymal stem cell, *EVs* extracellular vesicles, *H* human, *M* mouse, *R* rat, *BM* bone marrow, *AD* adipose tissue, *DP* dental pulp, *EMB* embryonic, *END* endometrial, *PL* placental, *UC* umbilical cord, *COX2* cyclooxygenase 2, *PGE*~*2*~ prostaglandin E~2~, *FGF19* fibroblast growth factor 19, *CCNB1* cyclin B1, *CDK8* cyclin-dependent kinase 8, *CDC6* cell division cycle 6, *VEGF* vascular endothelial growth factor, *PDGF-D* platelet-derived growth factor-D, *CCR2* C--C chemokine receptor type 2, *UBR2* ubiquitin protein ligase E3 component n-recognin 2, *TGF* tumor growth factor

### Protein effectors within MSC-EVs {#Sec3}

EVs generally include integral membrane proteins such as tetraspanins, peripheral membrane proteins, and cytosolic proteins, and changes in the protein composition of EVs have been shown to be associated with important functional changes \[[@CR30]\]. MSC-EVs also harbor numerous protein components that have been suggested to be linked with recovery from many diseases.

Vesicular protein effectors have been explored as a treatment for ischemia and myocardial infarction by promoting angiogenesis. For example, EVs from dental pulp-derived MSCs harbor the Jagged-1 ligand protein, which is an activator of Notch signaling, and they were shown to be effective in activating angiogenic signals \[[@CR31]\]. Jagged-1-containing EVs triggered transcriptional changes in Notch target genes in endothelial cells, resulting in induced angiogenesis and capillary-like tube information, and this angiogenic effect could be blocked with an anti-Jagged-1 antibody. In addition to this, UC-MSC-EVs have been shown to carry platelet-derived growth factor-D (PDGF-D), which has been shown to be effective in assisting tissue repair functions in infarcted heart cells \[[@CR32]\]. The recovery was abrogated by EVs isolated from MSCs transfected with PDGF-D-siRNA, thus suggesting that PDGF-D/PDGF receptor interactions might play a crucial role in EV-mediated myocardial repair.

In the context of bone regeneration, the therapeutic effect of vesicular CD73 is demonstrated by Zhang et al., in which CD73 present on EVs from embryonic stem cell-derived MSCs was able to repair osteochondral defects in chondrocyte cultures together with greater infiltration of macrophages with an anti-inflammatory phenotype. The role of CD73 in EVs was confirmed by Akt and extracellular signal-related kinase (Erk) signaling using a CD73 inhibitor \[[@CR33]\]. Also, a neuronal regeneration study was conducted to investigate the effect of BM-MSC-EVs for treating traumatic and degenerative ocular disease. It was shown that EVs harboring the argonaute-2 (AGO-2) protein promoted significant survival of retinal ganglion cells and regeneration of their axons. The effect was diminished by EVs from MSCs after knockdown of AGO-2, suggesting that AGO-2 is involved in the regenerative effects of EVs \[[@CR34]\].

On the basis of MSCs' well-known immunomodulatory effects, MSC-EVs have also been described as anti-inflammatory agents, thus rationalizing the use of EVs for the treatment of immune diseases, including renal injury. Harting et al. showed that the expression of cyclooxygenase 2 and prostaglandin E2 was increased in BM-MSC-EVs, and these components partially contributed to the attenuation of pro-inflammatory cytokines in splenocytes \[[@CR35]\]. Moreover, the quenching effect of the pro-inflammatory cytokine CCL2 by its receptor present on BM-MSC-EVs led to reduced macrophage activation and assisted in the repair of acute renal injury \[[@CR36]\]. In addition, delivery of 14-3-3ζ via EVs prevented the autophagic tubule epithelial cell injury that is normally induced by the chemotherapy drug cisplatin \[[@CR37]\].

Interestingly, MSC-derived EVs are not limited to only being beneficial in terms of tissue repair and anti-inflammatory effects that can be used therapeutically, and cancer cells can effectively exploit the MSCs' function for their own growth and immune escape. For example, fibroblast growth factor 19, which is present in BM-MSC-EVs, promotes nasopharyngeal carcinoma cell growth \[[@CR38]\]. Similarly, BM-MSC-EVs can deliver ubiquitin protein ligase E3 component n-recognin 2, which has proliferative and migratory effects on gastric cancer cells \[[@CR39]\].

Overall, MSCs' protein cargo can exert functional effects directly by quenching some of the factors that are pro-inflammatory or by enhancing anti-inflammatory factors. Some of the effects are likely to be combinatorial effects together with other cargos, thus dissecting these components one-by-one is a way forward in designing more effective MSC-EVs.

### Nucleic acids within MSC-EVs {#Sec4}

#### a. DNA {#FPar1}

Many forms of nucleic acids can be found within EVs, including DNA, mRNA, and miRNA. The existence and localization of DNA in EVs is still controversial, and there are no studies pointing towards the participation of DNA in the therapeutic effects of MSC-EVs. Interestingly, despite descriptions of pro-inflammatory effects of foreign DNA present in vesicles from other origins and uptake of them by MSCs \[[@CR40], [@CR41]\], we did not find any reports of inflammation induced by MSC-EV-associated DNA, suggesting that these EVs' immunosuppressive properties might overcome this possible effect or that there is less harmful DNA associated with MSC-EVs.

#### b. mRNA {#FPar2}

Few studies have attributed therapeutic effects to mRNAs when compared to the long list of studies that show at least correlations between specific miRNAs and observed outcomes, as can be seen in Table [1](#Tab1){ref-type="table"}. The stoichiometry of nucleic acids in EVs and the minimal concentration of each miRNA or mRNA needed to promote a robust effect in recipient cells is also still a subject of intense investigation \[[@CR42]\].

In acute lung injury models and in pneumonia, the mRNA for keratinocyte growth factor (KGF) has been implicated in the immunomodulation observed with MSC-EV treatment \[[@CR43], [@CR44]\]. In these studies, administration of an anti-KGF neutralizing antibody together with the treatment abrogated the beneficial effect initially observed on survival, and pretreatment of MSCs with siRNA against KGF transcripts also partially inhibited the anti-inflammatory effects of MSC-EVs as evidenced by bronchoalveolar lavage fluid cellularity and the presence of inflammatory cytokines. The authors further hypothesized that transcripts for angiopoietin-1, which is also abundant in MSC-EVs, play an important role in restoring lung protein permeability and in resolving inflammation through the use of MSC-EVs in vitro \[[@CR45]\] and in a murine model of acute lung injury \[[@CR46]\]. In fact, angiopoietin-1 siRNA pretreatment of MSCs or MSC-EVs led to a decrease in immunomodulation and permeability recovery across human lung microvascular endothelial cells in these models.

In an in vitro model of acute kidney injury, Ju and co-workers have suggested a particular role for hepatocyte growth factor mRNA because vesicles treated with RNase were shown to be ineffective in promoting dedifferentiation and subsequent growth of tubular cells \[[@CR47]\]. In another in vitro model of acute kidney injury induced by cisplatin, it was found that EV-associated mRNA for insulin-like growth factor 1 receptor was important for the protection of proximal tubular epithelial cells \[[@CR48]\]. In a similar cisplatin-induced in vitro model, interleukin (IL)-10 mRNA was also found to be transferred through MSC-EVs \[[@CR49]\].

Furthermore, mRNA for the synthesis of type VII collagen was found to be transferred in vitro to recessive dystrophic epidermolysis bullosa cells together with the collagen protein itself \[[@CR50]\]. This condition is characterized by loss-of-function mutations in the type VII collagen gene, and MSC-EVs might therefore be a potential treatment for this disease.

#### c. miRNA {#FPar3}

Increasing evidence has been provided for the effectiveness of miRNAs contained within MSC-EVs. Many miRNAs that are involved in the therapeutic effects of MSC-EVs in different disease conditions are shown in Fig. [2](#Fig2){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}.

Because the field of miRNA has been most extensively explored in cancer-related research, some of these miRNAs are known to be upregulated or are suggested to be markers in specific cancer types. However, this does not necessarily mean that the presence of these miRNAs in EVs represent a pro-tumorigenic risk because it is often the combination of multiple factors that is important for defining the ultimate role of each molecule in this process. Nevertheless, it is important to keep in mind that oncogenic molecules might be transferred through EVs and might influence the development of tumors when there is a lack of onco-suppressor genes in vivo \[[@CR51]\]. On the other hand, there might be only transient effects of this transfer in non-mutated cells \[[@CR52]\].

Generally speaking, among the miRNAs that are most frequently associated with the therapeutic properties of MSC-EVs, miR-21, miR-19a, and miR-210 are linked to cardiovascular diseases; miR-let-7b, miR-125a, and miR-21 are linked to wound healing; miR-21, miR-17-92, and miR-133b are linked to neural damage; miR-223, miR-146a, and miR-let-7c are linked to protection against hepatic and renal injuries; and miR-221, miR-1587, and miR-23b are linked to cancer-related effects (Fig. [2](#Fig2){ref-type="fig"}). Here, we will discuss in depth some of the miRNAs that are most often cited as possible mediators of MSC-EVs' effects. miR**-**21

Given that miR-21 has been shown to regulate cell survival by stimulating proliferation and by inhibiting apoptosis in different cell types \[[@CR53]\], the contribution of this miRNA has been connected with MSC-EV-mediated therapeutic effects in various disease models. BM-MSCs have been shown to deliver exogenous miR-21 via EVs and thus to prevent nucleus pulposus cell apoptosis and to reduce intervertebral disc degeneration \[[@CR54]\]. In addition, the expression of miR-21 has been shown to increase in MSC-EVs under hypoxic conditions, and injection of these MSC-EVs could reduce cognition and memory impairment in mice together with reduced plaque deposition and reduced activation of microglia \[[@CR55]\].

The function of miR-21 was further described by Fang et al. and Jackson et al. that EVs from UC-MSCs enriched with miR-21 play a key role in suppressing myofibroblast formation and thus in preventing excessive scar formation \[[@CR56], [@CR57]\]. Blocking miR-21 in these EVs abolished the ability of EVs to inhibit myofibroblast formation, suggesting that this specific miRNA is essential for the anti-scarring functions of MSCs.

miR-21 has also been described as having a protective role in cardiac injuries. EVs derived from BM-MSCs harbored increased levels of miR-21 after hydrogen peroxide-induced oxidation, and vesicular miR-21 could be transported to cardiac stem cells in order to functionally inhibit phosphatase and tensin homolog (PTEN) expression and thus protect against oxidative stress-triggered cell death \[[@CR58]\]. Another study showed that selective antagonism of miR-21 by anti-miR treatment eliminated the anti-apoptotic and angiogenic effects of MSC-EVs with subsequent upregulation of PTEN, a miR-21 target, suggesting that miR-21 might be a potential mediator of MSC-EVs' therapeutic effects against cardiovascular diseases \[[@CR59]\]. miR**-**145

miR-145 is related to the processes of cellular differentiation and the activation of smooth muscle cells and myofibroblasts \[[@CR60], [@CR61]\]. Moreover, miR-145 is often described as having tumor suppression effects \[[@CR62]--[@CR64]\]. In agreement with these finding, upregulation of miR-145 in MSC-EVs has been shown to be effective in skin defect healing and to have anti-tumor effects in prostate cancer \[[@CR56], [@CR65]\]. miR-145 is enriched in UC-MSC-derived EVs as determined by high-throughput RNA sequencing \[[@CR56]\]. Overexpression of miR-145 in EVs could suppress the activation of tumor growth factor (TGF)-β/SMAD2 leading to the inhibition of differentiation of fibroblasts into myofibroblasts, and depletion of this miRNA greatly abolished the ability of EVs to inhibit the TGF-β/SMAD2 pathway.

In terms of cancer prevention, AD-MSC-derived EVs significantly inhibited the proliferation of metastatic prostate cancer through apoptosis, and this effect was negated by miR-145 knockdown leading to reduced expression of Caspase 3/7 and increased expression of anti-apoptotic proteins \[[@CR65]\]. Interestingly, EVs secreted from UC-MSCs have been shown to inhibit hepatitis C virus (HCV) infection by suppressing viral infection, and this was largely attributed to suppression of viral RNA replication by miR-145 \[[@CR66]\]. miR**-**221

In contrast to miR-145, the facilitating role of miR-221 in cancer progression has been extensively recognized in recent years. For example, CD44 expression in hepatocellular carcinoma is controlled by miR-221 through the PI3K-Akt-mTOR pathway \[[@CR67]\]. Additionally, miR-221 can support non-small-cell lung carcinoma by targeting tissue inhibitor of metallopeptidases-2 \[[@CR68]\]. Similarly, high expression of miR-221 in EVs from BM-MSCs has been shown to effectively increase gastric cancer cell migration, invasion, and adhesion to the extracellular matrix \[[@CR69]\]. Another study using miR-221 showed that upregulated miR-221 in MSC-EVs protected against HCV in a similar manner as miR-145 mentioned above \[[@CR66]\].

How to make MSC-based therapies more potent? {#Sec5}
--------------------------------------------

### Biophysical cues {#Sec6}

MSCs have been shown to be stimulated by a variety of different biophysical and biochemical stimuli (Fig. [3](#Fig3){ref-type="fig"}). Biophysical inducers include electric pulsing \[[@CR70], [@CR71]\], low-power laser irradiation \[[@CR72]\], non-coherent red light \[[@CR73]\], electromagnetic field exposure \[[@CR74]\], mechanical cues (e.g., fluidics, tension, and pressure) and substrate topography and stiffness \[[@CR75]\], 2D and 3D scaffolds/scaffold-free culture \[[@CR76], [@CR77]\], and magnetic forces \[[@CR78]\]. Upon these different treatments, MSCs might dramatically change their phenotype and begin to differentiate into specific types of cells, which is useful for a range of applications such as tissue regeneration, especially in injuries to organs with mesenchymal origins \[[@CR79], [@CR80]\]. Nevertheless, some of these changes in the biophysical parameters of MSC culture can also influence their secretion profiles without promoting complete differentiation. Many of these treatments can, for example, increase the proliferation of MSCs, but little is known about their effects on EV secretion or their immunomodulation abilities, leaving a wide range of conditions to be explored in attempts to increase MSC-EV yields and to control their contents. Fig. 3The influence of various conditions on the production and function of EVs. The effects of culture conditions and external stimuli on MSC-EV secretion profiles and functional changes. MSC, mesenchymal stem cell; EVs, extracellular vesicles; LPS, lipopolysaccharide

In a study of EVs derived from MSCs subjected to 3D culture in type I collagen scaffolds versus common 2D cultures, the authors isolated EVs from their supernatants using a commercial kit and found greater amounts of protein and better outcomes in promoting functional recovery and immunomodulation in a model of traumatic brain injury in the samples isolated from 3D cultured cells \[[@CR79]\].

Another MSC culture parameter that can influence the yield of EVs is cell seeding density, with lower density being related to higher yields. It is, however, still unclear if these effects are related to cell-to-cell contact because multiple culture medium collections instead of one single collection over the same period of time also increases the number of EVs that can be collected. It is possible that EVs or metabolites present in the cell culture biochemically decrease the production and or secretion of EVs by MSCs \[[@CR80]\].

### Biochemical cues {#Sec7}

It is thought that MSCs responding to bacteria-derived molecules like lipopolysaccharides and the cytokines released in response to such molecules can increase their therapeutic effect against inflammatory environments \[[@CR81]--[@CR83]\]. More recently, EVs produced from MSCs under inflammatory conditions have gained increasing importance. A study done by Ti et al. has shown that lipopolysaccharide stimulation increases the secretion of EVs from UC-MSCs and enhances M2 macrophage polarization and diabetic cutaneous wound healing \[[@CR84]\]. Increasing evidence indicates that inflammatory cytokines might enhance the therapeutic efficacy of MSC-EVs \[[@CR35], [@CR85], [@CR86]\]. EVs from IL-1β-pretreated UC-MSCs were shown to have greater immunomodulatory effects than EVs from non-treated MSCs, suggesting that more functional molecules such as miR-146a were embedded in the EVs from IL-1β-pretreated MSCs \[[@CR85]\]. In line with this, MSC-EVs cultured in the presence of tumor necrosis factor alpha, interferon gamma, or TGF-β led to significantly decreased cytokine expression in splenocytes and to strongly increased regulatory T cell differentiation that in turn exerted an anti-inflammatory effect \[[@CR35], [@CR86]\].

MSC-CM includes various growth factors such as vascular endothelial growth factor and PDGF, and it mimics the beneficial effects associated with intact cells \[[@CR87], [@CR88]\]. The increased therapeutic effect induced by pre-stimulation with PDGF has been confirmed by Lopatina et al. on the basis of their work that use the angiogenic potential of AD-MSC-EVs for regenerative medicine \[[@CR89]\]. Also, hormone stimulation with erythropoietin increased the production of EVs and enhanced the protective effects of EVs following renal injury compared to untreated EVs \[[@CR90]\]. In addition, hypoxic and ischemic conditions have been shown to alter the characteristics of MSCs with respect to EV function. It is reported that hypoxia preconditioning causes BM-MSCs to increase the production of EVs and that these EVs have superior activity in cardiac protection by stimulating neovascularization \[[@CR91]\]. Also, EVs released by MSCs during nitric oxide stimulation have been shown to augment the angiogenic effects of endothelial cells and to restore limb function in hindlimb ischemia \[[@CR92]\]. Moreover, incorporation of paclitaxel into BM-MSC-EVs was shown to inhibit tumor growth in vitro \[[@CR93]\]. In addition, the serum contents of culture media were found to alter the MSC characteristics and the RNA contents of released EVs, suggesting that MSC-EVs can be modulated to contain different active components for future therapeutic applications \[[@CR94]\].

EVs derived from differentiated cells are able to modify the characteristics of MSCs. EVs from neuronal cells can mediate MSC neuronal induction via miR-125b transfer \[[@CR95]\], and endothelial cell-derived EVs influence MSC proliferation and migration, providing evidence for EVs as a communication channel between endothelial cells and MSCs \[[@CR96]\]. In addition, mast cell-derived EVs modulated MSC function to induce anti-inflammatory effects during ovalbumin-induced allergy model via vesicle-associated TGF-β \[[@CR97]\]. Moreover, EVs derived from tumor cells can also modulate the MSC phenotype. For example, EVs from cancer stem cells induce increased chemoattraction in MSCs resulting in tumor progression, and EVs from lung cancer cells stimulate the production and secretion of IL-6, IL-8, and monocyte chemoattractant protein-1 in MSCs, thus imbuing MSCs with more tumor-supportive characteristics \[[@CR98]\]. However, there are no well-defined studies on how other types of EVs might affect MSC function in terms of MSC-EVs despite the high probability that these EVs from differentiated cells will be able to modulate further EV production by MSCs. Therefore, research into the role of other cell-derived EVs on the potency of MSCs in terms of EV secretion will be needed in order to obtain optimal therapeutic outcomes.

### Cellular reprogramming of MSCs {#Sec8}

Despite the strong therapeutic effects of MSC-EVs, there is a need to further understand how genetic modification of MSCs can increase the therapeutic potency of secreted EVs. Researchers are currently trying to develop more therapeutically optimized MSCs through overexpression of proteins and miRNAs. Here, we will focus on how genetically modified MSC-EVs show altered cargo and improved functional effects.

#### a. Overexpressed proteins in MSCs {#FPar4}

Most proteins targeted for overexpression in MSCs have been transcription factors and signaling molecules. MSCs generally have limited expansion capability, thus Lai et al. have created immortalized MSCs by inducing overexpression of c-Myc. The production of EVs from these immortalized cells is scalable under stringent GMP conditions, and this enables these EVs to be used in the clinic \[[@CR99]\]. Another study showed that overexpression of the GATA-4 transcription factor in BM-MSCs increased the ability of their secreted EVs to improve cardiac function \[[@CR100]\]. Such EVs could transfer more miR-19a than EVs from control MSCs, thus resulting in restored cardiac contractile function and reduced infarct size in a mouse model. In addition, the hypoxia-inducible factor 1-α (HIF-1α) transcription factor is usually stabilized during ischemia and upregulates a variety of cardioprotective genes, and this led researchers to mutate the HIF-1α gene (oxygen-resistant form) in dental pulp-derived MSCs for application in treating ischemia-related disease \[[@CR101]\]. EVs from HIF-1α overexpressing MSCs had increased EV marker proteins such as tetraspanins and increased angiogenic activity compared to control EVs, and this led to increased repair of cardiac tissue in a mouse model \[[@CR31]\]. A similar study showed that EVs derived from BM-MSCs overexpressing HIF-1α were able to promote bone regeneration and to reduce steroid-induced avascular necrosis of the femoral head \[[@CR102]\]. Signaling molecules such as Akt have been exploited in MSCs to increase their effectiveness. EVs from UC-MSCs that overexpress Akt harbor higher levels of Akt than control EVs, and this leads to accelerating proliferation, migration, and vessel formation in endothelial cells thus resulting in greater efficiency of cardiac repair. This effect is mediated by enhanced PDGF-D production in endothelial cells that promotes angiogenesis in the ischemic heart \[[@CR32]\]. Some indications of these cardioprotective effects of Akt-overexpressing MSC-EVs were seen in the CM, and the effects were attributed to secreted frizzled-related protein 2 \[[@CR103]\].

MSCs reside in close proximity to tumor cells and are reported to be involved in tumor progression \[[@CR104]\]. It has been generally considered that the tumor microenvironment can alter the contents of MSC-EVs and lead them towards a more pro-tumorigenic phenotype. For instance, Roccaro et al. showed that BM-MSC-EVs from multiple myeloma patients have different contents of tumor suppressor miRNAs than EVs from normal healthy subjects, and these patient-derived EVs promoted multiple myeloma tumor growth, whereas EVs from healthy individuals inhibited the growth of tumor cells \[[@CR105]\]. Thus, genetic modification of MSCs has also been investigated in terms of how they affect tumor growth. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to be a promising agent for cancer therapy \[[@CR106]\], and based on this, Tuan et al. transfected this gene into MSCs and then measured the cancer cell-killing efficacy of EVs derived from these cells. Such EVs were decorated with highly expressed TRAIL and induced apoptosis in various cancer cell lines but not in primary bronchial cells \[[@CR106], [@CR107]\]. In addition to gene overexpression, the effect of tumor-related gene knockdown has also been characterized in BM-MSCs. EVs from p53-deficient BM-MSCs were enriched in a UBR2 protein that promotes gastric cancer progression. Such regulation of the p53 oncogene that indirectly targets UBR2 to target cells enhanced tumor growth and metastasis by regulating the Wnt/β-catenin pathway \[[@CR39]\].

#### b. Overexpression of miRNA in MSCs {#FPar5}

The use of miRNAs that target transcriptional and posttranscriptional regulation might offer a novel option for treating many diseases. However, the advancement of miRNA therapy has been hindered by obstacles in delivering miRNA to the target organs. EVs have emerged as an effective vehicle for delivering miRNA, thus many researchers have been engineering MSCs to load miRNA into EVs and have seen potent therapeutic effects (Table [2](#Tab2){ref-type="table"}). Table 2Overview of gene-transfected MSC studies conducted in in vitro and in vivo modelsMSC originModelIn vivo*/*in vitro potencyTransgeneRef.H - BMGlioblastomaIncreased survival in glioma stem cell-injected micemiR-124a\[[@CR144]\]H - BMBreast cancerDecreased tumor activity and sizemiR-379\[[@CR145]\]H - BMRenal fibrosisDecreased matrix depositionmiR-let-7c\[[@CR108]\]H - SYNDiabetes skin defectIncreased proliferation of fibroblasts and epithelial cellsmiR-126\[[@CR117]\]H - SYNOsteoarthritisIncreased cartilage tissue regenerationmiR-140-5p\[[@CR116]\]H - UCGlioblastoma (in vitro)Decreased proliferation and migration and increased chemosensitivitymiR-124\[[@CR111]\]H - UCBurn-induced inflammationDecreased inflammationmiR-181c\[[@CR146]\]H/M - ADLiver fibrosisInhibited fibrosismiR-122\[[@CR109]\]H/M - ADHepatocarcinomaInhibited tumor growthmiR-122\[[@CR110]\]Marrow stromal cellsGliomaInhibited tumor growthmiR-146b\[[@CR112]\]M - ADLiver fibrosisIncreased autophagymiR-181-5p\[[@CR147]\]M - BMAutoimmune hepatitisRecovery from liver injurymiR-223\[[@CR115]\]R - BMMyocardial infarctionImproved cardiac function and reduced infarction sizemiR-19a\[[@CR100]\]R - BMCortical neuron activation (in vitro)Increased axonal growthmiR-17-92\[[@CR113]\]R - BMIntracerebral hemorrhageNeuroprotective effectsmiR-133b\[[@CR114]\]R - BMAcute myocardial infarctionIncreased cardiac functionmiR-133\[[@CR148]\]R - BMCardiomyocyte activation (in vitro)Increased survival after hypoxia in cardiomyocytesmiR-221\[[@CR149]\]Abbreviations: *MSC* mesenchymal stem cell, *H* human, *M* mouse, *R* rat, *BM* bone marrow, *AD* adipose tissue, *UC* umbilical cord, *SYN* synovial

A mouse renal injury and liver fibrosis model was used to study the anti-fibrotic effect of EV-mediated miR-let7c and miR-122. In this mouse model, EVs released from MSCs, which had been engineered to overexpress miR-let7c, included abundant miR-let7c and were able to attenuate kidney injury and to significantly downregulate the expression of TGF-β1 and downstream fibrotic genes in the kidney, thus providing a prime example of the use of engineered MSCs for therapeutic delivery of miRNA via EVs \[[@CR108]\]. Given that miR-122 plays a crucial role in liver fibrosis by negatively regulating the proliferation of hepatic cells, miR-122 was modified in AD-MSCs to produce EVs with increased levels of miR-122. These EVs mediated the communication between MSCs and hepatic stellate cells through miR-122-induced downregulation of target genes such as insulin-like growth factor receptor-1, cyclin G-1, and prolyl-4-hydroxylase α-1 \[[@CR109]\].

In addition to the anti-fibrotic effect of EV-associated miR-122, the same miR-122-containing EVs made hepatocellular carcinoma cancer cells more sensitive to the chemotherapeutic effects of sorafenib \[[@CR110]\]. In line with this, other miRNA modifications have been shown to endow MSC-EVs with anti-tumor effects. In order to mitigate the difficulties in targeting miRNAs to glioblastoma multiforme, Wharton's jelly-MSCs were overexpressed with miR-124, and the derived EVs enhanced chemosensitivity to temozolomide and decreased the migration of glioblastoma cells \[[@CR111]\]. In another study, rat brain MSC-EVs overexpressing miR-146b were used to reduce the tumor burden of glioma xenografts, and intra-tumor administration of these EVs reduced glioma growth in the rat brain \[[@CR112]\].

The neuroprotective activities of miR-17-92 and miR-133 have been augmented in EVs from miRNA-expressing MSCs. EVs harvested from MSCs transfected with miR-17-92 showed significantly increased axonal growth of cortical neurons characterized by higher axonal elongation speed compared to control EVs \[[@CR113]\]. In an intracerebral hemorrhage rat model, miR-133-containing MSC-EVs were able to generate a pro-survival signaling response that helped to stop the degeneration of neurons, and this was mediated by suppression of RhoA and activation of the Erk172/cAMP response element-binding protein \[[@CR114]\].

Studies have also examined the regenerative effects of miRNAs delivered by MSC-EVs in different disease models. EVs from miR-223-overexpressing BM-MSCs were used in a mouse model of autoimmune hepatitis, and the EVs could prevent liver injury through miR-223-induced downregulation of target cytokine expression and downregulation of NLR pyrin domain containing 3 and caspase-1 activity \[[@CR115]\]. Moreover, a study on EVs derived from miR-140-5p-overexpressing human synovial MSCs showed enhanced cartilage tissue regeneration and reduced osteoarthritis of the knee in a rat model \[[@CR116]\], and EVs derived from miR-126-overexpressing human synovial MSCs healed full-thickness skin defects in a diabetic rat model \[[@CR117]\].

Conclusions and perspectives {#Sec9}
============================

The relationships between EV components and EVs' biological effects have also been investigated, and the most commonly identified molecules are proteins and miRNAs. Various strategies for exogenously loading isolated EVs with specific proteins and nucleic acids have been investigated \[[@CR118]\], for example, electroporation, freeze-thaw cycles, saponin-mediated loading, and hypotonic dialysis \[[@CR119]\]. Moreover, many groups have started to pack EVs with desired cargos using transgenic MSCs that are genetically modified to overexpresses certain proteins and miRNAs. However, this requires optimized conditions in order for genetically modified EVs to acquire more effective functional properties. In addition, comprehensive studies are needed regarding the quality control of EV compositions as well as the safety and efficacy of these EVs before they can be used in clinical applications.

Before addressing the benefits of MSC-EVs over MSCs, it is essential to consider the need for careful investigation of the following issue. The effects of various external factors on the properties of MSCs have been described in numerous clinical trials \[[@CR120]\]. Subtle differences in donor variance, senescence, cell culture methods, and immunogenicity were shown to make the functional alteration in MSC therapy. For instance, MSCs undergoing cellular senescence promoted metabolic dysfunction \[[@CR121]\] and lost their mesenchymal plasticity and anti-inflammatory effect \[[@CR120]\], which might be leading to failures of MSC therapy. To our knowledge, there have been no studies assessing the relationship between EV therapeutic activities and MSC senescence. However, it needs further investigation on senescent cell contents when EVs are functionally evaluated, and in-depth understanding of the related mechanism will contribute to successful development of MSC-EVs for clinical use.

In conclusion, MSCs have potential therapeutic functions through various vesicular components together with the cells themselves and their secreted soluble factors, and MSCs are amenable to modifications that improve the quantity and effectiveness of the EVs they produce. Thus MSC-derived EVs can be harnessed as powerful therapeutic agents to deliver anti-inflammatory and regenerative compounds in many different diseases. Future work will focus on developing bioengineered MSCs that produce significantly increased yields of EVs that can safely transfer a wide variety of potent and effective therapeutic molecules.

Additional file
===============

 {#Sec10}

Additional file 1:Table S1 Overview of MSC-EVs studies. There are total 126 published articles that address the therapeutic function of EVs in a variety of disease models. (XLSX 19 kb)

AD

:   Adipose tissue

AGO-2

:   Argonaute-2

BM

:   Bone marrow

CM

:   Conditioned media

Erk

:   Extracellular signal related kinase

EVs

:   Extracellular vesicles

HCV

:   Hepatitis C virus

HIF

:   Hypoxia-inducible factor

IL

:   Interleukin

KGF

:   Keratinocyte growth factor

MSCs

:   Mesenchymal stem cells

MVs

:   Microvesicles

PDGF

:   Platelet-derived growth factor

PTEN

:   Phosphatase and tensin homolog

TGF

:   Tumor growth factor

TRAIL

:   Tumor necrosis factor-related apoptosis-inducing ligand

UC

:   Umbilical cord blood
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